Quarterly report pursuant to Section 13 or 15(d)

Segments

v3.19.2
Segments
6 Months Ended
Jun. 30, 2019
Segment Reporting [Abstract]  
SEGMENTS SEGMENTS
We manage our operations in two reportable segments, pharmaceutical and diagnostics. The pharmaceutical segment consists of our pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain, Rayaldee product sales and our pharmaceutical research and development. The diagnostics segment primarily consists of our clinical laboratory operations through BioReference and our point-of-care operations. There are no significant inter-segment sales. We evaluate the performance of each segment based on operating profit or loss. There is no inter-segment allocation of interest expense and income taxes.
Information regarding our operations and assets for our operating segments and the unallocated corporate operations as well as geographic information are as follows:
 
For the three months ended June 30,
 
For the six months ended June 30,
(In thousands)
2019
 
2018
 
2019
 
2018
Revenue from services:
 
 
 
 
 
 
 
Pharmaceutical
$

 
$

 
$

 
$

Diagnostics
178,458

 
216,055

 
357,349

 
427,369

Corporate

 

 

 

 
$
178,458

 
$
216,055

 
$
357,349

 
$
427,369

Revenue from products:
 
 
 
 
 
 
 
Pharmaceutical
$
28,680

 
$
28,523

 
$
53,981

 
$
56,374

Diagnostics

 

 

 

Corporate

 

 

 

 
$
28,680

 
$
28,523

 
$
53,981

 
$
56,374

Revenue from transfer of intellectual property and other:
 
 
 
 
 
 
 
Pharmaceutical
$
19,230

 
$
19,107

 
$
37,490

 
$
34,855

Diagnostics

 

 

 

Corporate

 

 

 

 
$
19,230

 
$
19,107

 
$
37,490

 
$
34,855

Operating loss:
 
 
 
 
 
 
 
Pharmaceutical
$
(8,556
)
 
$
2,165

 
$
(38,033
)
 
$
(20,783
)
Diagnostics
(28,013
)
 
1,475

 
(61,582
)
 
(6,543
)
Corporate
(10,691
)
 
(8,748
)
 
(22,962
)
 
(20,393
)
 
$
(47,260
)
 
$
(5,108
)
 
$
(122,577
)
 
$
(47,719
)
Depreciation and amortization:
 
 
 
 
 
 
 
Pharmaceutical
$
7,382

 
$
6,752

 
$
14,908

 
$
13,492

Diagnostics
16,260

 
17,989

 
32,530

 
35,975

Corporate
19

 
21

 
39

 
51

 
$
23,661

 
$
24,762

 
$
47,477

 
$
49,518

Loss from investment in investees:
 
 
 
 
 
 
 
Pharmaceutical
$
(271
)
 
$
(6,942
)
 
$
(2,125
)
 
$
(9,114
)
Diagnostics

 
(271
)
 

 
(555
)
Corporate

 

 

 

 
$
(271
)
 
$
(7,213
)
 
$
(2,125
)
 
$
(9,669
)
Revenues:
 
 
 
 
 
 
 
United States
$
184,310

 
$
222,535

 
$
369,203

 
$
437,845

Ireland
22,174

 
20,778

 
42,707

 
38,060

Chile
9,051

 
11,937

 
16,915

 
23,670

Spain
4,876

 
4,592

 
9,294

 
10,125

Israel
3,768

 
2,526

 
6,884

 
6,141

Mexico
2,058

 
1,302

 
3,589

 
2,723

Other
131

 
15

 
228


34

 
$
226,368

 
$
263,685

 
$
448,820

 
$
518,598


(In thousands)
June 30,
2019
 
December 31,
2018
Assets:
 
 
 
Pharmaceutical
$
1,239,338

 
$
1,236,499

Diagnostics
1,138,673

 
1,162,160

Corporate
78,217

 
52,413

 
$
2,456,228

 
$
2,451,072

Goodwill:

 

Pharmaceutical
$
247,055

 
$
247,407

Diagnostics
452,787

 
452,786

Corporate

 

 
$
699,842

 
$
700,193



No customer represented more than 10% of our total consolidated revenue during the three and six months ended June 30, 2019 and 2018. As of June 30, 2019 and December 31, 2018, no customer represented more than 10% of our accounts receivable balance.